Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News VentriPoint Diagnostics Ltd VPTDF


Primary Symbol: V.VPT

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in... see more

Recent & Breaking News (TSXV:VPT)

Children's Hospital in Western Canada to Become First to Use Ventripoint Heart Analysis System for 3D Echocardiograms

TheNewsWire August 21, 2019

Ventripoint Announces $2,000,000 Non-Brokered Private Placement and Cross Trade

TheNewsWire August 16, 2019

Ventripoint Commends Mazankowski Alberta Heart Institute on their Feasibility Study Finding the VMS+ System Can Obviate the Need for Contrast Agents for LV Volumes and EF

TheNewsWire August 6, 2019

Ventripoint Manufacturing Facility Passed Inspection and First Two VMS+ 3.0 Heart Analysis Machines Shipping to Western Canada

TheNewsWire July 31, 2019

A Second Canadian Heart Institute to Receive Ventripoint VMS+ 3.0 Whole-Heart Analysis System

TheNewsWire July 23, 2019

A Canadian Heart Institute to Receive Ventripoint VMS+ 3.0 Whole-Heart Analysis System

TheNewsWire July 16, 2019

Canadian Children's Hospital to Receive Ventripoint VMS+ 3.0 For Clinical Assessment of Pediatric Cardiac Patients

TheNewsWire July 15, 2019

Ventripoint Receives CE Mark for Clinical Use of VMS+ 3.0 Whole-Heart Analysis System

TheNewsWire July 2, 2019

(AUDIO ENHANCED!) Ventripoint VMS+3.0 Whole-Heart Analysis System Receives License for Clinical Use from Health Canada

TheNewsWire June 25, 2019

Ventripoint to Exhibit VMS+ Technology at the American Society of Echocardiography Annual Scientific Sessions

TheNewsWire June 21, 2019

Ventripoint Completes Usability Study for VMS+ 3.0 with Positive Results

TheNewsWire June 17, 2019

Ventripoint to Manufacture VMS+ 3.0 In-House at Toronto Headquarters

TheNewsWire June 10, 2019

Ventripoint Files Regulatory Submissions for Next-Generation VMS+ 3.0 System in Major Markets

TheNewsWire June 5, 2019

Ventripoint Achieves Major Milestone by Passing External Safety Testing for Next-Generation VMS+ 3.0

TheNewsWire May 31, 2019

Ventripoint Featured in Canadian Business Quarterly for Paving a New Path in Cardiology Care with its AI-Powered Technology

TheNewsWire May 21, 2019

Ventripoint Signs an Authorized Sales Agent Agreement with Irudigi

TheNewsWire May 15, 2019

Ventripoint to Exhibit VMS+ 3.0 at the Canadian Society of Echocardiography 21st Annual Symposium

TheNewsWire April 1, 2019

Canada's Largest Heart Health Centre Orders VMS+ Complete Heart Analysis System

TheNewsWire March 25, 2019

Ventripoint Provides Live Demonstrations of the VMS+3.0 System at American College of Cardiology 68th Annual Conference

TheNewsWire March 19, 2019

Ventripoint Announces TSXV Approval of Extension of Warrants and Clarifies Warrants Subject to Extension

TheNewsWire March 14, 2019